Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$0.94 USD
+0.05 (6.09%)
Updated May 1, 2024 03:58 PM ET
After-Market: $0.94 0.00 (0.50%) 6:06 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AXDX 0.94 +0.05(6.09%)
Will AXDX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AXDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXDX
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
AXDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics
Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System
Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for AXDX
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (STAA), DarioHealth (DRIO) and Accelerate Diagnostics (AXDX)
Accelerate Diagnostics price target lowered by $1 at Craig-Hallum, here's why
Stockholders Beware: Accelerate Diagnostics’ Surge in Authorized Shares Signals Potential Dilution Risk
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results
AXDX Stock Earnings: Accelerate Diagnostics Misses EPS, Misses Revenue for Q4 2023